BCTX
BriaCell Therapeutics Corp - New (BCTX)
Healthcare • NASDAQ • $3.03+1.34%
- Symbol
- BCTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.03
- Daily Change
- +1.34%
- Market Cap
- $25.23M
- Trailing P/E
- N/A
- Forward P/E
- -7.44
- 52W High
- $31.60
- 52W Low
- $2.60
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 1.64
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications …
Company websiteResearch BCTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.